Table 1 Demographic and clinical characteristics of study participants. Data shown as median (interquartile range) or n (%). Data are reported at time of plasma biomarker assessment.

From: Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

 

Viral suppression

Untreated HIV

Cases

n = 77

Controls

n = 77

Cases

n = 42

Controls

n = 42

Demographics

 Age (years)

36.0 (31.0, 44.0)

35.0 (31.0, 41.0)

36.0 (29.8, 44.5)

37.0 (29.3, 42.0)

 Female

16 (20.8%)

16 (20.8%)

16 (38.1%)

22 (52.4%)

Race

 Black

23 (29.9%)

19 (24.7%)

28 (66.7%)

14 (33.3%)

 Latino/Hispanic

7 (9.1%)

20 (26.0%)

5 (11.9%)

8 (19.0%)

 Asian

23 (29.9%)

10 (13.0%)

1 (2.4%)

7 (16.7%)

 White

24 (31.2%)

28 (36.4%)

8 (19.0%)

12 (28.6%)

 Other

0 (0.0%)

0 (0.0%)

0 (0.0%)

1 (2.4%)

Region

 Africa

21 (27.3%)

17 (22.1%)

25 (59.5%)

14 (33.3%)

 Asia

23 (29.9%)

10 (13.0%)

1 (2.4%)

7 (16.7%)

 Europe/Israel/Australia

15 (19.5%)

23 (29.9%)

3 (7.1%)

10 (23.8%)

 Latin America

10 (13.0%)

20 (26.0%)

11 (26.2%)

10 (23.8%)

 United States

8 (10.4%)

7 (9.1%)

2 (4.8%)

1 (2.4%)

HIV history

Likely mode of HIV infection

 Injection drug use

1 (1.3%)

1 (1.3%)

0 (0.0%)

0 (0.0%)

 Male sexual contact with person of same sex

47 (61.0%)

51 (66.2%)

12 (28.6%)

15 (35.7%)

 Sexual contact with person of opposite sex

27 (35.1%)

23 (29.9%)

30 (71.4%)

24 (57.1%)

 Other/unknown

2 (2.6%)

2 (2.6%)

0 (0.0%)

3 (7.1%)

 Years HIV positive

0.8 (0.3, 3.0)

0.9 (0.3, 2.1)

1.6 (0.5, 3.4)

2.1 (0.8, 5.5)

HIV lab data

 CD4 + T cell count (cells/mm3)

747 (621, 947)

747 (628, 880)

722 (583, 831)

674 (580, 838)

 CD8 + T cell count (cells/mm3)

806 (628, 925)

723 (573, 963)

926 (745, 1115)

961 (709, 1288)

 CD4 + /CD8 + ratio

0.99 (0.76, 1.24)

1.01 (0.73, 1.31)

0.77 (0.55, 1.05)

0.74 (0.51, 0.90)

 HIV-RNA (log10 copies/ml)

1.3 (1.3, 1.6)

1.3 (1.3, 1.6)

3.8 (3.1, 4.3)

3.9 (3.4, 4.4)

Medical history at study entry

 Body mass index (kg/m2)

25.2 (21.2, 27.0)

24.1 (22.0, 27.3)

25.5 (21.6, 27.4)

24.0 (21.8, 28.4)

 Current smoker

19 (24.7%)

19 (24.7%)

11 (26.2%)

11 (26.2%)

 Prior cardiovascular disease

0 (0%)

0 (0%)

0 (0%)

0 (0%)

 Hypertension

15 (80.5%)

9 (11.7%)

10 (23.8%)

5 (11.9%)

 Diabetes

1 (1.3%)

1 (1.3%)

0 (0%)

0 (0%)

 Hepatitis B or C

4 (5.2%)

5 (6.5%)

1 (2.4%)

2 (4.8%)

Lung function, at first included measurement

 FEV1 (l)

3.54 (3.01, 4.01)

3.64 (2.85, 4.15)

3.15 (2.72, 3.58)

2.86 (2.24, 3.75)

 FVC (l)

4.20 (3.54, 5.11)

4.44 (3.56, 5.05)

3.72 (3.26, 4.53)

3.53 (2.85, 4.71)

 FEV1/FVC ratio

0.83 (0.80, 0.86)

0.82 (0.80, 0.85)

0.83 (0.79, 0.87)

0.84 (0.78, 0.88)

 < 0.7

4 (5.2%)

0 (0%)

0 (0%)

4 (9.5%)

 < Lower limit of normala

4 (5.2%)

1 (1.3%)

1 (2.4%)

2 (4.8%)

 FEV1 as % of predicted1

97.1 (86.4, 105.0)

95.6 (88.2, 102.9)

95.6 (89.8, 102.0)

95.7 (85.1, 107.7)

  1. FEV1 forced expiratory volume in 1-s, FVC forced vital capacity, HIV human immunodeficiency virus, START strategic timing of antiretroviral therapy.
  2. aFrom Global Lung Function Initiative (GLI) 2012 equations32.
Back to article page